A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer

Anticancer Research

Volumn 20, Issue 6 D, 2000, Pages 5099-5105

  Lufter D ^a   Richter, A ^a   Gunther S ^a   Flath, B ^a   Akrivakis, C ^a   Geppert, R ^a   Wernecke, K D ^a   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

A27.29; Bone metastases; Breast cancer; Deoxypyridinoline; DPD crosslinks

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CALCIUM; DEOXYPYRIDINOLINE; PAMIDRONIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; BONE METASTASIS; BREAST CANCER; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 0034450635     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
2. Reduction in new metastases with adjuvant clodronate treatment
3. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
4. Markers of bone resorption in patients treated with pamidronate
5. The course of the urinary crosslinks secretion in metastatic breast cancer - A possibility for response assessment
6. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast cancer
7. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer
8. Molecular basis and clinical application of biological markers of bone turnover
9. Aspects of bone remodeling
10. Different effects of bisphospohonate and estrogen therapy on free and peptide-bound bone cross-links excretion
11. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial
12. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
13. The bone isoenzyme of alkaline phosphatase in hypercalcaemic cancer patients
14. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease
15. Clinical and technical evaluation of ACS BR assay of MUC-1 gene-derived glycoprotein in breast cancer and comparison with CA15-3
16. Relationship between CA15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease
17. Urinary free deoxypyridinoline: Comparison of a new automated chemiluminescence immunoassay with HPLC and ELISA techniques
18. Performance characteristics of the ACS™ BR: A comparison with three other assays that also measure CA15-3
19. Changes with age in the excretion of lysyl- and hydroxylysylpyridinoline. Two new markers of bone collagen turnover
20. Isoenzymes of alkaline phosphatase - Useful parameters for identification of bone metastasis in prostatic carcinoma?
21. The diagnostic value of urinary pyridinium-crossslinks of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic disease
22. Calcium extention (Ca E) in metastatic breast cancer
23. Serum concentrations of type I carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and amino-terminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer
24. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers